Sarcoidal Granulomatous Panniculitis Associated with Immune Checkpoint Inhibitors: A Rare Immune-Mediated Cutaneous Adverse Event
DOI:
https://doi.org/10.51987/rev.hosp.ital.b.aires.v45i1.354Keywords:
Sarcoidosis, cancer, immunotherapy, immune checkpointAbstract
Immune checkpoint inhibitors (ICIs), or checkpoint inhibitors, have been associated with various inflammatory and autoimmune adverse effects, known as immune-related adverse events (irAEs). Among irAEs, dermatological toxicities are the most prevalent, with maculopapular rash, pruritus, and lichenoid and psoriasiform eruptions being the most common.
Downloads
References
Trilleras-Gómez AP, Hull KJ, Drew DZ. Case report and review of 7 similar cases in the literature: cutaneous sarcoidosis as side effect of pembrolizumab plus chemotherapy in stage IV squamous cell carcinoma of lung. J Immunother. 2021;44(2):90-94. https://doi.org/10.1097/CJI.0000000000000351. DOI: https://doi.org/10.1097/CJI.0000000000000351
Torres-Jiménez J, Esteban-Villarrubia J, García-Abellás P, et al. Sarcoidosis-like reactions in cancer patients treated with immune checkpoint inhibitors: experience in a Spanish hospital. Clin Transl Oncol. 2021;23(7):1474-1480. https://doi.org/10.1007/s12094-020-02546-w. DOI: https://doi.org/10.1007/s12094-020-02546-w
Chorti E, Kanaki T, Zimmer L, et al. Drug-induced sarcoidosis-like reaction in adjuvant immunotherapy: Increased rate and mimicker of metastasis. Eur J Cancer. 2020;131:18-26. https://doi.org/10.1016/j.ejca.2020.02.024. DOI: https://doi.org/10.1016/j.ejca.2020.02.024
Juan-Carpena J, Palazón-Cabanes JC, Blanes-Martínez M. Revisión sistemática de los efectos adversos cutáneos causados por fármacos inhibidores de los puntos de control inmunitario: características, manejo y pronóstico. Actas Dermosifiologr. 2022;113(4):376-387. https://doi.org/10.1016/j.ad.2021.09.005. DOI: https://doi.org/10.1016/j.ad.2021.09.005
Suozzi KC, Stahl M, Ko CJ, et al. Immune-related sarcoidosis observed in combination ipilimumab and nivolumab therapy. JAAD Case Rep. 2016;2(3):264-268. https://doi.org/10.1016/j.jdcr.2016.05.002. DOI: https://doi.org/10.1016/j.jdcr.2016.05.002
Martínez Leboráns L, Esteve Martínez A, Victoria Martínez AM, et al. Cutaneous sarcoidosis in a melanoma patient under Ipilimumab therapy. Dermatol Ther. 2016;29(5):306-308. https://doi.org/10.1111/dth.12380. DOI: https://doi.org/10.1111/dth.12380
Birnbaum MR, Ma MW, Fleisig S, et al. Nivolumab-related cutaneous sarcoidosis in a patient with lung adenocarcinoma. JAAD Case Rep. 2017;3(3):208-211. https://doi.org/10.1016/j.jdcr.2017.02.015. DOI: https://doi.org/10.1016/j.jdcr.2017.02.015
Chanson N, Ramos-Casals M, Pundole X, et al. Immune checkpoint inhibitor-associated sarcoidosis: a usually benign disease that does not require immunotherapy discontinuation. Eur J Cancer. 2021;158:208-216. https://doi.org/10.1016/j.ejca.2021.05.041. DOI: https://doi.org/10.1016/j.ejca.2021.05.041
Sibaud V. Dermatologic reactions to immune checkpoint inhibitors : skin toxicities and immunotherapy. Am J Clin Dermatol. 2018;19(3):345-361. https://doi.org/10.1007/s40257-017-0336-3. DOI: https://doi.org/10.1007/s40257-017-0336-3
Haanen JBAG, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl_4):iv119-iv142. https://doi.org/10.1093/annonc/mdx225. Errata en: Ann Oncol. 2018;29(Suppl 4):iv264-iv266. https://doi.org/10.1093/annonc/mdy162. DOI: https://doi.org/10.1093/annonc/mdx225
Abdelghaffar M, Hwang E, Damsky W. Cutaneous sarcoidosis. Clin Chest Med. 2024;45(1):71-89. https://doi.org/10.1016/j.ccm.2023.08.004. DOI: https://doi.org/10.1016/j.ccm.2023.08.004
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Revista del Hospital Italiano de Buenos Aires
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
